Neuropsychiatric Events Associated with Leukotriene-Modifying Agents: A Systematic Review
- 166 Downloads
Leukotriene-modifying agents (LTMAs) including montelukast, zafirlukast, and zileuton are approved by the US Food and Drug Administration (FDA) for the treatment of asthma and allergic rhinitis. Various neuropsychiatric events (NEs) have been reported; however, the evidence of the association is conflicting. This systematic review investigates the association between NEs and LTMAs by assessing the relevant published literature.
PubMed, EMBASE, MEDLINE, and Cochrane Library were searched using keywords. Studies designed to investigate the association were eligible for inclusion without restriction to any study design or language. The primary outcome was defined as suicidal conditions, while secondary outcomes included all other NEs.
Thirty-three studies were included for a narrative review. Four observational studies did not find a significant association, while ten pharmacovigilance studies using different global databases detected the signals. Notably, some studies suggest that the FDA warning issued in 2008 might have influenced the reporting rate of NEs as a result of increased awareness.
The risk of NEs was not quantified, because of the lack of randomized controlled trials and observational studies investigating the association.
Many pharmacovigilance studies have been conducted to determine the association between NEs and LTMAs, but there is limited evidence from observational studies. High-quality epidemiological studies should be conducted to evaluate the association and quantify the risk, not only in children, but also in adults.
We thank Joseph E. Blais (Centre for Safe Medication Practice and Research) for proofreading the manuscript.
Compliance with Ethical Standards
The study was partially supported by a grant from the Research Grants Council of the Hong Kong Special Administrative Region, China (Project No. HKU 789813).
Conflict of interest
Sharon W.Y. Law, Angel Y.S. Wong, Shweta Anand, Ian C.K. Wong, and Esther W. Chan declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.US Food and Drug Administration (FDA). Accolate (zafirlukast) product label. 2013. http://www.fda.gov/Drugs. Accessed 14 Nov 2016.
- 2.US Food and Drug Administration (FDA). Zyflo (zileuton) product label. 2012. http://www.fda.gov/Drugs. Accessed 14 Nov 2016.
- 3.US Food and Drug Administration (FDA). Singulair (montelukast sodium) product label. 2014. http://www.fda.gov/Drugs. Accessed 14 Nov 2016.
- 14.US Food and Drug Administration (FDA). Updated information on leukotriene inhibitors: montelukast (marketed as Singulair), zafirlukast (marketed as Accolate), and zileuton (marketed as Zyflo and Zyflo CR). 2015. http://www.fda.gov/Drugs. Accessed 23 Dec 2016.
- 15.Scott SGM. Singulair, Montelukast: asthma medication linked to serious psychotic episodes in children. ABC News, Australia. 2016. http://www.abc.net.au/news/2016-09-05/asthma-tablet-linked-to-serious-psychotic-episodes-in-children/7795474. Accessed 16 Nov 2016.
- 25.Cheng J. Adverse drug reactions induced by montelukast. Chin J New Drugs. 2014;23(4):486–8 (92).Google Scholar
- 35.Gadde DP, Creticos PS, Beakes DE, Dauby PL, Grooms LA, Abeel D, et al. Adverse effects associated with leukotriene antagonist therapy. J Allergy Clin Immunol. 2010;1:AB68.Google Scholar
- 36.Aldea-Perona A, Fernandez-Quintana E, Garcia-Sanchez-Colomer M, Boada-Fernandez del Campo C, Rodriguez-Jimenez C, Sanz-Alvarez E, et al. Up-to-date of the neuropsychiatric events in relation with antileukotriens-agents in the Spanish surveillance system (Sistema Espanol de Farmacovigilancia-SEFV). Basic Clin Pharmacol Toxicol. 2011;109:35.CrossRefGoogle Scholar
- 37.Iessa N, Star K, Wilton L, Curran S, Edwards IR, Aronson JK, et al. Montelukast and suicide: causality assessment using spontaneous reports and Bradford Hill guidelines. Drug Saf. 2011;34:949–50.Google Scholar
- 38.Rhee CW, Choi NK, Ahn YO, Lee J, Park BJ. Risk of depression associated with use of leukotriene receptor antagonist in elderly asthma patients in Korea. Pharmacoepidemiol Drug Saf. 2011;20:S251.Google Scholar
- 39.Trotta F, Tartaglia L, Ferrazin F, Santuccio C. Psychiatric and behaviour-related adverse events occurring with antiasthmatic drugs reported in the national pharmacovigilance network. Drug Saf. 2011;34:1013–4.Google Scholar
- 40.Iessa N, Murray M, Wong I, Man K, Frank B, Santosh P, et al. Leukotriene receptor antagonists and suicide: a self-controlled case series study. Drug Saf. 2013;36:855.Google Scholar
- 41.Burgos Pimentel ABP, De Francisco AM, Tavakov A, Avendano JF, Jimenez TD, Perez TC, et al. Neuropsychiatric disorders associated with montelukast. Allergy. 2014;69:439.Google Scholar
- 43.Erdem SB, Karaman S, Nacaroglu HT, Unsal Karkiner CS, Can D. Are leukotriene receptor antagonists safe? Allergy. 2015;70:412–3.Google Scholar
- 51.Kalra J, Kumar P, Majeed ABA, Prakash A. Modulation of LOX and COX pathways via inhibition of amyloidogenesis contributes to mitoprotection against beta-amyloid oligomer-induced toxicity in an animal model of Alzheimer’s disease in rats. Pharmacol Biochem Behav. 2016;146–147:1–12.CrossRefPubMedGoogle Scholar